Eli Lilly welcomes you to a focused clinical webinar exploring the evolving paradigm of type 2 diabetes management beyond HbA1c reduction toward holistic metabolic improvement. In this session, the speaker will discuss how traditional glucose-centric targets may not fully capture the complex cardiometabolic nature of diabetes, highlighting the importance of addressing multiple metabolic parameters. The discussion will examine the limitations of relying solely on HbA1c and the growing emphasis on comprehensive metabolic control for improved long-term outcomes.
The webinar will also review emerging clinical evidence supporting incretin-based therapies and their effects across multiple cardiometabolic risk factors beyond glycemic control. Through an evidence-based overview, the session will highlight how these therapies contribute to broader metabolic benefits, reinforcing a shift toward…
